Curis Inc (CRIS) Stock Price & Analysis

Curis Inc (CRIS) fell 4.89% to USD 0.45 as of June 10, 2026 at 05:37 UTC, according to Nexqual real-time market data.

CRIS last closed at USD 0.47; the session ranged USD 0.44–0.48 on volume of 250,960 shares. Market capitalization is $17.43M, with a 52-week range of USD 0.44–3.13 (NCM). Source: Nexqual, June 10, 2026 at 05:37 UTC.

Key Statistics (as of June 10, 2026 at 05:37 UTC)

Technical Analysis (CRIS)

Nexqual's technical model rates CRIS "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:37 UTC.

Analyst Ratings (CRIS)

Wall Street analysts rate CRIS "None" based on 3 analysts, with a mean price target of USD 14 (range USD 5–20), per Nexqual as of June 10, 2026 at 05:37 UTC.

Earnings (CRIS)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 05:37 UTC.

Financials & Fundamentals (CRIS)

Source: Nexqual, June 10, 2026 at 05:37 UTC.

Financial Health Score (CRIS)

Nexqual rates Curis Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:37 UTC.

Ownership (CRIS)

Source: Nexqual, June 10, 2026 at 05:37 UTC.

Leadership (CRIS)

Curis Inc is led by James E. Dentzer (age 58), President, CEO, Secretary, Treasurer & Director, per Nexqual as of June 10, 2026 at 05:37 UTC.

Major Backers & Investors (CRIS)

Notable institutional backers of Curis Inc include Bleichroeder LP, Stonepine Capital Management, LLC, Nantahala Capital Management, LLC, according to Nexqual as of June 10, 2026 at 05:37 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 05:37 UTC.

From Curis Inc's Latest SEC 10-K Filing (filed 2026-03-24)

Key Strengths & Strategy (as disclosed to the SEC)

• In March 2025, we announced that we had completed productive meetings with both the European Committee for Medicinal Products for Human Use, or CHMP, and the FDA on the suitability of using the ongoing TakeAim Lymphoma Phase 1/2 study to support a potential accelerated regulatory path for a Conditional Marketing Authorization, or CMA, submission in Europe and a New Drug Application, or NDA, submission in the U.S.
• With passage of the FDA's Modernization Act 2.0 in December 2022, Congress eliminated provisions in both the FDCA and the Public Health Service Act, or PHSA, that required animal testing in support of an NDA.
• FDA regulations allow access to investigational drugs under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the drug under a treatment protocol, or Treatment IND Application.
• Intellectual Property Our policy is to obtain and enforce the patents and proprietary technology rights that are key to our business.

Partnerships

• In conjunction with the October 2016 exercise of our option to license the PD-L1/TIM3 program under our collaboration with Aurigene and the March 2018 exercise of our option to the fourth program in immuno-oncology, we obtained world-wide (except for India and Russia) exclusive licenses to the Aurigene intellectual 11 Table o f Contents property relevant to the program.
• We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:37 UTC. This page is informational and not investment advice.